Choose VHH-His when you need a compact, usually monomeric nanobody for screening, binding assays, structural work, or applications where an Fc domain could interfere. Choose VHH-Fc when you want an Fc-fused, typically dimeric construct that may improve apparent avidity, support Fc-based detection, or extend persistence in an animal model. For veterinary medicine, the key additional question is whether the Fc species and biological activity are appropriate for the target animal. Neither format is universally better: select based on the assay, intended use, and required downstream handling.
You can find more information on our web, so please take a look.
VHH-His consists of a VHH domain fused to a polyhistidine purification tag, commonly a 6×His tag. VHH-Fc links the VHH to an immunoglobulin Fc region; Fc fusion commonly promotes dimerization, although the final behavior depends on the construct and production system. The added Fc also changes molecular size, purification options, detection methods, and potential interactions with Fc receptors or other Fc-binding components.
| Consideration | VHH-His | VHH-Fc |
|---|---|---|
| Construct | VHH with a His purification tag | VHH fused to an immunoglobulin Fc domain |
| Typical format behavior | Often a compact, single-chain reagent | Often forms a larger, Fc-associated dimer |
| Common purification route | Immobilized metal affinity chromatography may be suitable | Protein A or Protein G may be suitable, depending on the Fc |
| Potential advantage | Small format and straightforward screening flexibility | Potential avidity and Fc-based detection or handling options |
| Important check | Confirm that the tag does not affect the assay | Confirm species compatibility and account for Fc-mediated effects |
A VHH is the antigen-binding domain of a heavy-chain-only antibody, and a His tag is a short sequence of histidine residues used to facilitate purification or detection. A 6×His tag contains six histidine residues, but the tag itself does not establish that the VHH will bind well or behave as a monomer under every condition. The final protein’s properties depend on its sequence, linker design, expression host, purification, and storage conditions.
Because VHH-His lacks an Fc domain, it is often a useful starting format when comparing candidate binders or developing assays that need a relatively small binding reagent. It can be purified using a compatible metal-affinity method, though purification performance should be confirmed for the specific construct. Researchers should also consider whether the tag could affect binding, background, or downstream readouts, particularly when the assay detects the tag directly.
In a VHH-Fc construct, the VHH is genetically fused to an immunoglobulin Fc region. Fc regions commonly associate to form dimers, which can give a construct two VHH binding domains and may increase apparent binding through avidity when the target presents suitable geometry. This effect is assay- and target-dependent; it should not be interpreted as proof that the intrinsic affinity of each VHH domain has changed.
An Fc fusion can also support Fc-based capture or detection and may alter circulation behavior in vivo. However, these properties depend on Fc sequence, species, glycosylation, and the biology of the intended animal model. A mammalian expression system is often selected when appropriate folding or glycosylation is important, but expression host choice should be made against the project’s functional requirements rather than assumed to guarantee a particular activity.
VHH-His is a practical choice for early-stage binder screening, biochemical characterization, and many in vitro assays where a compact construct is desirable. It may also be preferable when Fc-receptor binding or Fc-mediated detection could confound the result. For structural or mechanistic studies, the smaller format can be helpful, although researchers should confirm that the tag and any linker are compatible with the experimental design.
In veterinary diagnostics, VHH-His may suit a capture or detection reagent when the assay design can use a tag-specific reagent or another compatible detection strategy. It is important to test background in the actual sample matrix, such as serum or other animal-derived material, rather than relying only on buffer-based results. The format does not remove the need to validate specificity, sensitivity, and cross-reactivity for the intended species and sample type.
VHH-Fc can be appropriate when a dimeric presentation or Fc-based detection method benefits the assay. It may also be considered for animal studies where longer persistence is a project objective, but the relevant FcRn interaction and Fc behavior should be evaluated in the target species. A construct intended for a canine study, for example, should not be assumed to behave like one containing a species-matched Fc simply because both include an Fc domain.
For veterinary research, Fc can introduce biological interactions that are either useful or undesirable. Depending on the Fc and model, interactions with Fc receptors, complement components, or anti-Fc reagents may influence observed results. Include an appropriate Fc-only control when Fc-dependent effects could be mistaken for VHH-mediated activity.
If you want to learn more, please visit our website NBbiolab.
A VHH domain commonly has a molecular mass in the approximate range of 12–15 kDa, while an Fc fusion is larger and may exist as an associated dimer. These are planning ranges rather than specifications: sequence, linkers, glycosylation, and expression system affect the measured mass and product profile. Ask the supplier to provide the expected construct design and available characterization data for the requested molecule.
Decide whether your experiment requires one binding domain per molecule or could benefit from two-domain presentation. If the target is multivalent or displayed at high density, VHH-Fc may produce stronger apparent binding through avidity, while a monovalent VHH-His can help distinguish intrinsic binding behavior. Test both formats when the biological interpretation depends on separating affinity from avidity.
His-tagged proteins are often purified by immobilized metal affinity chromatography, while some Fc fusions can be purified using Protein A or Protein G. These are common options, not guaranteed outcomes; the chosen resin, Fc subtype, construct design, and product quality requirements all matter. Confirm the purification method and any residual-tag or polishing requirements before ordering.
For animal studies, specify the species, route, dosing plan, and intended observation period when requesting an Fc format. FcRn binding and Fc-receptor interactions can vary by species, so a human Fc should not automatically be treated as functionally equivalent to a veterinary-species Fc. If species matching is not feasible, plan pilot studies and controls to characterize the limitation.
VHH-His and VHH-Fc should be compared as complete project specifications, not only as construct names. An Fc fusion may require a different expression and purification workflow, and additional characterization may be appropriate for aggregation, purity, or biological activity. These requirements can affect cost and lead time, but the impact depends on sequence, scale, host, and requested deliverables.
When requesting a quote, provide the VHH sequence or sequence status, preferred tag or Fc species, expression host preference, target quantity, application, and required analytical tests. Ask whether the quote includes construct design, expression, purification, and product documentation. For veterinary projects, state the target animal species and whether Fc-mediated function is required, merely tolerated, or specifically undesirable.
NBbiolab supports recombinant nanobody expression projects by helping buyers translate an application into a construct and production brief. For a VHH-His request, the brief can specify tag position, expression host, purification approach, and intended assay. For VHH-Fc, it should additionally identify the desired Fc species or subtype and whether dimerization, Fc-based detection, or in vivo persistence is part of the objective.
Before production, align on sequence, construct boundaries, scale, purity target, formulation, and requested analytical documentation. If the best format is uncertain, discuss a staged plan: evaluate a compact VHH-His candidate first, then produce an Fc fusion for applications that justify its added size and biology. This approach can help avoid paying for a more complex format before its value has been established.
Use VHH-His when compactness, monovalent interpretation, or reduced Fc-related interference is the priority. Use VHH-Fc when Fc-based detection, dimeric presentation, or a potentially longer in vivo persistence is relevant and the Fc is suitable for the intended species. In veterinary medicine, species compatibility and Fc-mediated background deserve explicit attention before selecting the construct.
Your next step is to define the assay or animal model, decide whether Fc effects are wanted, and specify the required product quantity and characterization. If those requirements are unclear, request a consultation with NBbiolab to compare construct options before committing to expression. A format choice grounded in the intended use is more informative than selecting by tag name alone.
Contact us to discuss your requirements of When to Use VHH-His vs VHH-Fc Expression Formats. Our experienced sales team can help you identify the options that best suit your needs.